Subject Index to Volume 3

INDEX Reviews in Urology Subject Index to Volume 3 111 Peehl DM. Basic science of hormonal therapy for prostate cancer. 3(suppl 3):S15–S22. Interstitial cystitis and bladder research: progress and future directions [Meeting Review]. 3(3):146–151. Androgen receptor Peehl DM. Basic science of hormonal therapy for prostate cancer. 3(suppl 3):S15–S22. Apomorphine Rajfer J. Duplex scans, apomorphine, and Peyronie disease [Literature Review]. 3(1):23–24. Abacterial prostatitis Special report on prostatitis: state of the art [Meeting Review]. 3(2):94–98. Angiography Grasso M, Caruso RP, Phillips CK. UPJ obstruction in the adult population: are crossing vessels significant? 3(1):42–50, 61. Artificial neural networks Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Acute urinary retention Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. 3(4):187–192. Antibiotic prophylaxis Decter RM. Update on vesicoureteral reflux: pathogenesis, nephropathy, and management. 3(4):172–178. Autoimmunity Special report on prostatitis: state of the art [Meeting Review]. 3(2):94–98. Adjuvant hormone therapy Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. 3(suppl 3):S23–S28. Nickel JC. Antibiotic therapy for interstitial cystitis? [Literature Review]. 3(3):155–156. In-capromab pendetide scan Han M, Partin AW. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint ® Scan, Cyt-356). 3(4):165–171. 5-reductase Fagelman E, Lowe FC. Saw palmetto berry as a treatment for BPH. 3(3):134–138. Afferent blockade Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Alternative medicine Moyad MA, Sakr WA, Hirano D, Miller GJ. Complementary medicine for prostate cancer: effects of soy and fat consumption. 3(suppl 2):S20–S30. Androgen blockade Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. 3(suppl 3):S1–S9. Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. Anticholinergic therapy Appell RA. Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. 3(suppl 1):S15–S18. Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Lepor H. A comparison of anticholinergic therapies in the treatment of overactive bladder [Literature Review]. 3(4):209. Anti-inflammatory therapy Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Antiproliferative factor Yoshimura N, Chancellor MB. Bacille Calmette-Guérin vaccine French CG, Hickey L, Bell DG. Caseating granulomas on the glans penis as a complication of bacille Calmette-Guérin intravesical therapy. 3(1):36–39, 61. Benign mass Kim IY, Sadeghi F, Slawin KM. Dyspareunia: an unusual presentation of leiomyoma of the bladder. 3(3):152–154. Benign prostatic hyperplasia Conlin M. Current and coming in endourology [Meeting Review]. 3(1):6–9. Fagelman E, Lowe FC. Saw palmetto berry as a treatment for BPH. 3(3):134–138. Roehrborn CG. Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options VOL. 3 NO. 4 2001 REVIEWS IN UROLOGY 217 Subject Index continued [Meeting Review]. 3(3):139–145. Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. 3(4):187–192. Biomarkers Freedland SJ, Bui MHT, Chao D, et al. Biomarkers for early detection and optimized treatment for transitional cell carcinoma [Literature Review]. 3(4):210–212. Bisphophonates Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. Bladder cancer Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Freedland SJ, Chao D, Pantuck AJ, et al. Determining the optimal treatment for advanced bladder cancer [Literature Review]. 3(3):159–162. Bladder dysfunction Decter RM. Update on vesicoureteral reflux: pathogenesis, nephropathy, and management. 3(4):172–178. Bladder mass Kim IY, Sadeghi F, Slawin KM. Dyspareunia: an unusual presentation of leiomyoma of the bladder. 3(3):152–154. Bladder outlet obstruction Roehrborn CG. Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options [Meeting Review]. 3(3):139–145. Bladder tumor antigen tests Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. BLCA-4 test Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Blockade of flare Thompson, Ian. Flare associate with LHRH-agonist therapy. 3(suppl 218 VOL. 3 NO. 4 2001 3):S23–S28. Brachytherapy Korb LJ, Brawer MK. Modern brachytherapy for localized prostate cancers: the Northwest Hospital experience. 3(1):51–60. Roach M III, Thrasher JB, Blasko J, et al. Prostatectomy, brachytherapy, intensity-modulated radiotherapy, hormonal-radiotherapy, salvage cryosurgery, and the role of combined hormonal blockade in the treatment of prostate cancer. 3(suppl 2):S49–S58. Capsaicin Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Carcinoma, renal Conlin M. Current and coming in endourology [Meeting Review]. 3(1):6–9. Chemotherapy Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. Chili pepper Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Chronic pelvic pain syndrome Special report on prostatitis: state of the art [Meeting Review]. 3(2):94–98. CK20 test Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Complementary medicine Moyad MA, Sakr WA, Hirano D, Miller GJ. Complementary medicine for prostate cancer: effects of soy and fat consumption. 3(suppl 2):S20–S30. Compliance Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. Complications French CG, Hickey L, Bell DG. REVIEWS IN UROLOGY Caseating granulomas on the glans penis as a complication of bacille Calmette-Guérin intravesical therapy. 3(1):36–39, 61. Computed tomography Freedland SJ, Eilber KS, Palapattu GS, Rajfer J. Conservative management of a grade 4 renal laceration in a child. 3(1):40–41. Cost of treatment Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. Cryoablation Pound CR, Brawer MD, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. 3(2):72–84. Cryosurgery Roach M III, Thrasher JB, Blasko J, et al. Prostatectomy, brachytherapy, intensity-modulated radiotherapy, hormonal-radiotherapy, salvage cryosurgery, and the role of combined hormonal blockade in the treatment of prostate cancer. 3(suppl 2):S49–S58. Cryptorchidism Shapiro E. Paternity and hormone levels [Literature Review]. 3(2):108–109. Shapiro E. Update in pediatric urology [Meeting Review]. 3(1):10–17. Cyclooxygenase-2 Partin AW. Cyclooxygenase-2 as a marker for prostate cancer [Literature Review]. 3(2):107–108. Cystectomy Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Cystectomy, radical Freedland SJ, Chao D, Pantuck AJ, et al. Determining the optimal treatment for advanced bladder cancer [Literature Review]. 3(3):159–162. Cystitis Nickel JC. International symposium on UTI management [Meeting Review]. 3(1):18–19. Subject Index Detrusor-sphincter dyssynergia Zisman A, Pantuck AJ, Freedland SJ, Belldegrun AS. Urology in the desert 2000 [Meeting Review]. 3(2):99–101. Diet Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Erectile aids Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. 3(3):113–119. Flutamide Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. Erectile dysfunction Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Gene therapy Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Djavan B, Yasutomo N. Prostate cancer gene therapy—what have we learned and where are we going? 3(4):177–186. Yoshimura N, Chancellor MB. Interstitial cystitis and bladder research: progress and future directions [Meeting Review]. 3(3):146–151. Gerota’s fascia Stifelman MD, Sosa RE, Shichman SJ. Hand-assisted laparoscopy in urology. 3(2):63–71. Diethylstilbestrol Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. 3(suppl 3):S1–S9. Lynch JH, Batuello JT, Crawford ED, et al. Therapeutic strategies for localized prostate cancer. 3(suppl 2):S39–S48. Digital rectal examination Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. 3(3):113–119. Diuretic renogram Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. DNA ploidy Miller GJ, Brawer MK, Sakr WA, et al. Prostate cancer: serum and tissue markers. 3(suppl 2):S11–S19. Duplex scan Rajfer J. Duplex scans, apomorphine, and Peyronie disease [Literature Review]. 3(1):23–24. E-cadherin Miller GJ, Brawer MK, Sakr WA, et al. Prostate cancer: serum and tissue markers. 3(suppl 2):S11–S19. Enuresis Shapiro E. Update in pediatric urology [Meeting Review]. 3(1):10–17. Environmental factors Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Epidemiology Nitti V. The prevalence of urinary incontinence. 3(suppl 1):S2–S6. Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. 3(4):187–192. Epidermal growth factor Yoshimura N, Chancellor MB. Interstitial cystitis and bladder research: progress and future directions [Meeting Review]. 3(3):146–151. Rajfer J. Duplex scans, apomorphine, and Peyronie disease [Literature Review]. 3(1):23–24. Etiology Nitti V. The prevalence of urinary incontinence. 3(suppl 1):S2–S6. Exisuland Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. External beam radiation therapy Korb LJ, Brawer MK. Modern brachytherapy for localized prostate cancers: the Northwest Hospital experience. 3(1):51–60. Pound CR, Brawer MD, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. 3(2):72–84. Fat Moyad MA, Sakr WA, Hirano D, Miller GJ. Complementary medicine for prostate cancer: effects of soy and fat consumption. 3(suppl 2):S20–S30. FDP test Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Fertility Shapiro E. Paternity and hormone levels [Literature Review]. 3(2):108–109. Gleason score Pound CR, Brawer MD, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. 3(2):72–84. Gonadotropin-releasing hormone agonists Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. 3(suppl 3):S23–S28. Gonadotropin-releasing hormone antagonists Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. 3(suppl 3):S1–S9. Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. 3(suppl 3):S23–S28. HA/HAase test Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Hand-assisted laparoscopy Stifelman MD, Sosa RE, Shichman VOL. 3 NO. 4 2001 REVIEWS IN UROLOGY 219 Subject Index continued SJ. Hand-assisted laparoscopy in urology. 3(2):63–71. Hematuria Freedland SJ, Eilber KS, Palapattu GS, Rajfer J. Conservative management of a grade 4 renal laceration in a child. 3(1):40–41. Heparin-binding epidermal growth factor-like growth factor Yoshimura N, Chancellor MB. Interstitial cystitis and bladder research: progress and future directions [Meeting Review]. 3(3):146–151. Hernia Eilber KS, Freedland SJ, Rajfer J. Obstructive uropathy secondary to ureteroinguinal herniation. 3(4):207–208. Herpes simplex virus Yoshimura N, Chancellor MB. Interstitial cystitis and bladder research: progress and future directions [Meeting Review]. 3(3):146–151. Hormonal therapy Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. Lynch JH, Batuello JT, Crawford ED, et al. Therapeutic strategies for localized prostate cancer. 3(suppl 2):S39–S48. Peehl DM. Basic science of hormonal therapy for prostate cancer. 3(suppl 3):S15–S22. Hydronephrosis Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)192–205. Grasso M, Caruso RP, Phillips CK. UPJ obstruction in the adult population: are crossing vessels significant? 3(1):42–50, 61. Hypercalciuria Shapiro E. Hypercalciuria in pediatric stone formers [Literature Review]. 3(1):20. Hypospadias Shapiro E. Update in pediatric urology [Meeting Review]. 3(1):10–17. Hysterectomy Leng WW, Chancellor MB. Comparison of incontinence risk after radical prostatectomy versus hysterectomy [Literature Review]. 3(3):156–159. Immunomodulatory genes Djavan B, Yasutomo N. Prostate cancer gene therapy—what have we learned and where are we going? 3(4):177–186. Incidence Nitti V. The prevalence of urinary incontinence. 3(suppl 1):S2–S6. Incontinence, urinary Appell RA. Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. 3(suppl 1):S15–S18. Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Roach M III, Thrasher JB, Blasko J, et al. Prostatectomy, brachytherapy, intensity-modulated radiotherapy, hormonal-radiotherapy, salvage cryosurgery, and the role of combined hormonal blockade in the treatment of prostate cancer. 3(suppl 2):S49–S58. Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. 3(suppl 3):S23–S28. Dmochowski R. Evaluating the effectiveness of therapies for urinary incontinence. 3(suppl 1):S7–S14. Hospice care Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. Leng WW, Chancellor MB. Comparison of incontinence risk after radical prostatectomy versus hysterectomy [Literature Review]. 3(3):156–159. 220 VOL. 3 NO. 4 2001 REVIEWS IN UROLOGY Chancellor MB, Smith CP. What is the best sling material: autologous fascia, cadaveric fascia, synthetic strip, or in situ vaginal wall? [Literature Review]. 3(1):28–29. Nitti V. The prevalence of urinary incontinence. 3(suppl 1):S2–S6. Steers W. Potential targets in the treatment of urinary incontinence. 3(suppl 1):S19–S26. Infertility Paduch DA, Skoog SJ. Current management of adolescent variocele. 3(3):120–133. Rajfer J. Men undergoing ICSI: Y we do what we do [Literature Review]. 3(4):213. Rajfer J. The Y chromosome and infertility [Literature Review]. 3(3):155. Special report on prostatitis: state of the art [Meeting Review]. 3(2):94–98. Insulin-like growth factor Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. 3(suppl 2):S31–S38. Miller GJ, Brawer MK, Sakr WA, et al. Prostate cancer: serum and tissue markers. 3(suppl 2):S11–S19. Intensity-modulated radiotherapy Roach M III, Thrasher JB, Blasko J, et al. Prostatectomy, brachytherapy, intensity-modulated radiotherapy, hormonal-radiotherapy, salvage cryosurgery, and the role of combined hormonal blockade in the treatment of prostate cancer. 3(suppl 2):S49–S58. Internet Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Interstitial cystitis Nickel JC. Antibiotic therapy for interstitial cystitis? [Literature Review]. 3(3):155–156. Yoshimura N, Chancellor MB. Interstitial cystitis and bladder research: progress and future directions [Meeting Review]. 3(3):146–151. Intracytoplasmic sperm injection Rajfer J. Men undergoing ICSI: Y we do what we do [Literature Review]. 3(4):213. Rajfer J. The Y chromosome and infertility [Literature Review]. 3(3):155. Subject Index Kidney Freedland SJ, Eilber KS, Palapattu GS, Rajfer J. Conservative management of a grade 4 renal laceration in a child. 3(1):40–41. Laparoscopy Conlin M. Current and coming in endourology [Meeting Review]. 3(1):6–9. Grasso M, Caruso RP, Phillips CK. UPJ obstruction in the adult population: are crossing vessels significant? 3(1):42–50, 61. Zisman A, Pantuck AJ, Freedland SJ, Belldegrun AS. Urology in the desert 2000 [Meeting Review]. 3(2):99–101. Laval University Prostate Cancer Screening Program Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Leiomyoma Kim IY, Sadeghi F, Slawin KM. Dyspareunia: an unusual presentation of leiomyoma of the bladder. 3(3):152–154. Lower urinary tract symptoms O’Leary M, Chancellor MB. Is nighttime voiding normal or anomalous? [Literature Review]. 3(2):106–107. Roehrborn CG. Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options [Meeting Review]. 3(3):139–145. Luteinizing hormone-releasing hormone Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. 3(suppl 3):S1–S9. Thompson, Ian. Flare associate with LHRH-agonist therapy. 3(suppl 3):S10–S14. Lymph node Han M, Partin AW. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint® Scan, Cyt-356). 3(4):165–171. Metastasis Woo K, Wieczorek R, Torre P, Lepor H. Prostate adenocarcinoma present- ing as a large clavicular mass. 3(2):102–105. Metastatic cascade Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Microsurgical inguinal repair Paduch DA, Skoog SJ. Current management of adolescent variocele. 3(3):120–133. Muscle-derived stem cells Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Nocturia O’Leary M, Chancellor MB. Is nighttime voiding normal or anomalous? [Literature Review]. 3(2):106–107. Obstruction Eilber KS, Freedland SJ, Rajfer J. Obstructive uropathy secondary to ureteroinguinal herniation. 3(4):207–208. Oncogenes Djavan B, Yasutomo N. Prostate cancer gene therapy—what have we learned and where are we going? 3(4):177–186. Nephrectomy Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Overactive bladder Appell RA. Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. 3(suppl 1):S15–S18. Stifelman MD, Sosa RE, Shichman SJ. Hand-assisted laparoscopy in urology. 3(2):63–71. Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Nephroureterectomy Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Dmochowski R. Evaluating the effectiveness of therapies for urinary incontinence. 3(suppl 1):S7–S14. Stifelman MD, Sosa RE, Shichman SJ. Hand-assisted laparoscopy in urology. 3(2):63–71. Nerve growth factor Steers W. Potential targets in the treatment of urinary incontinence. 3(suppl 1):S19–S26. Neuroendocrine cells Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. Neurokinin Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Neuroplasticity Steers W. Potential targets in the treatment of urinary incontinence. 3(suppl 1):S19–S26. NMP22 test Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Lepor H. A comparison of anticholinergic therapies in the treatment of overactive bladder [Literature Review]. 3(4):209. Steers W. Potential targets in the treatment of urinary incontinence. 3(suppl 1):S19–S26. Oxybutinin Appell RA. Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. 3(suppl 1):S15–S18. Pediatric urology Freedland SJ, Eilber KS, Palapattu GS, Rajfer J. Conservative management of a grade 4 renal laceration in a child. 3(1):40–41. Shapiro E. Hypercalciuria in pediatric stone formers [Literature Review]. 3(1):20. Shapiro E. Proteinuria in children [Literature Review]. 3(1):30. Penis French CG, Hickey L, Bell DG. Caseating granulomas on the glans penis as a complication of bacille VOL. 3 NO. 4 2001 REVIEWS IN UROLOGY 221 Subject Index continued Calmette-Guérin intravesical therapy. 3(1):36–39, 61. Peyronie disease Rajfer J. Duplex scans, apomorphine, and Peyronie disease [Literature Review]. 3(1):23–24. Phenotyping Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Phytotherapy Fagelman E, Lowe FC. Saw palmetto berry as a treatment for BPH. 3(3):134–138. Special report on prostatitis: state of the art [Meeting Review]. 3(2):94–98. Polyamine depletion Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. Positron emission tomography Miller GJ, Brawer MK, Sakr WA, et al. Prostate cancer: serum and tissue markers. 3(suppl 2):S11–S19. Prevalence Nitti V. The prevalence of urinary incontinence. 3(suppl 1):S2–S6. ProstaScint Han M, Partin AW. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint® Scan, Cyt-356). 3(4):165–171. Prostate biopsy Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. 3(suppl 2):S31–S38. Prostate cancer Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. 3(suppl 3):S1–S9. Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. 222 VOL. 3 NO. 4 2001 REVIEWS IN UROLOGY Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Djavan B, Yasutomo N. Prostate cancer gene therapy—what have we learned and where are we going? 3(4):177–186. Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. 3(suppl 2):S31–S38. Han M, Partin AW. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint® Scan, Cyt-356). 3(4):165–171. Korb LJ, Brawer MK. Modern brachytherapy for localized prostate cancers: the Northwest Hospital experience. 3(1):51–60. Lynch JH, Batuello JT, Crawford ED, et al. Therapeutic strategies for localized prostate cancer. 3(suppl 2):S39–S48. Moyad MA, Sakr WA, Hirano D, Miller GJ. Complementary medicine for prostate cancer: effects of soy and fat consumption. 3(suppl 2):S20–S30. Partin AW. Cyclooxygenase-2 as a marker for prostate cancer [Literature Review]. 3(2):107–108. Peehl DM. Basic science of hormonal therapy for prostate cancer. 3(suppl 3):S15–S22. Potter SR, Partin AW. Laparoscopic radical prostatectomy [Literature Review]. 3(1):22–23. Roach M III, Thrasher JB, Blasko J, et al. Prostatectomy, brachytherapy, intensity-modulated radiotherapy, hormonal-radiotherapy, salvage cryosurgery, and the role of combined hormonal blockade in the treatment of prostate cancer. 3(suppl 2):S49–S58. Thompson, Ian. Flare associate with LHRH-agonist therapy. 3(suppl 3):S10–S14. Woo K, Wieczorek R, Torre P, Lepor H. Prostate adenocarcinoma presenting as a large clavicular mass. 3(2):102–105. Zisman A, Pantuck AJ, Freedland SJ, Belldegrun AS. Urology in the desert 2000 [Meeting Review]. 3(2):99–101. Prostatectomy, radical Korb LJ, Brawer MK. Modern brachytherapy for localized prostate cancers: the Northwest Hospital experience. 3(1):51–60. Leng WW, Chancellor MB. Comparison of incontinence risk after radical prostatectomy versus hysterectomy [Literature Review]. 3(3):156–159. Lynch JH, Batuello JT, Crawford ED, et al. Therapeutic strategies for localized prostate cancer. 3(suppl 2):S39–S48. Roach M III, Thrasher JB, Blasko J, et al. Prostatectomy, brachytherapy, intensity-modulated radiotherapy, hormonal-radiotherapy, salvage cryosurgery, and the role of combined hormonal blockade in the treatment of prostate cancer. 3(suppl 2):S49–S58. Prostatectomy, radical laparoscopic Potter SR, Partin AW. Laparoscopic radical prostatectomy [Literature Review]. 3(1):22–23. Prostate gland, enlarged Roehrborn CG. Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options [Meeting Review]. 3(3):139–145. Prostate-specific antigen Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Miller GJ, Brawer MK, Sakr WA, et al. Prostate cancer: serum and tissue markers. 3(suppl 2):S11–S19. Subject Index Review]. 3(1):18–19. Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. Tumor vaccines for metastatic renal cell carcinoma [Literature Review]. 3(1):21. Pound CR, Brawer MD, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. 3(2):72–84. Pyeloplasty Grasso M, Caruso RP, Phillips CK. UPJ obstruction in the adult population: are crossing vessels significant? 3(1):42–50, 61. Prostate-specific antigen testing Roehrborn CG. Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options [Meeting Review]. 3(3):139–145. Quality of life, health-related Brawer MK, Crawford ED, Labrie F, et al. Androgen deprivation and other treatments for advanced prostate cancer. 3(suppl 2):S59–S68. Renal scarring Decter RM. Update on vesicoureteral reflux: pathogenesis, nephropathy, and management. 3(4):172–178. Prostatic fossa Han M, Partin AW. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint® Scan, Cyt-356). 3(4):165–171. Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. 3(3):113–119. Resiniferitoxin Chancellor MB. Future trends in the treatment of urinary incontinence. 3(suppl 1):S27–S34. Quality of life instruments Dmochowski R. Evaluating the effectiveness of therapies for urinary incontinence. 3(suppl 1):S7–S14. Retroperitoneal ligation Paduch DA, Skoog SJ. Current management of adolescent variocele. 3(3):120–133. Radiofrequency ablation Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Risk factors Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. 3(4):187–192. Prostatism Roehrborn CG. Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options [Meeting Review]. 3(3):139–145. Prostatitis Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Nickel JC. Diagnosis and management of prostatitis: the American approach [Literature Review]. 3(1):27. Nickel JC. International symposium on UTI management [Meeting Review]. 3(1):18–19. Special report on prostatitis: state of the art [Meeting Review]. 3(2):94–98. Proteinuria Shapiro E. Proteinuria in children [Literature Review]. 3(1):30. Psychometric test theory Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. 3(3):113–119. Pubovaginal sling Chancellor MB, Smith CP. What is the best sling material: autologous fascia, cadaveric fascia, synthetic strip, or in situ vaginal wall? [Literature Review]. 3(1):28–29. Pyelonephritis Nickel JC. International symposium on UTI management [Meeting Radiolabeled monoclonal antibody Han M, Partin AW. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint® Scan, Cyt-356). 3(4):165–171. Radiologic staging Miller GJ, Brawer MK, Sakr WA, et al. Prostate cancer: serum and tissue markers. 3(suppl 2):S11–S19. Receptor blockade Steers W. Potential targets in the treatment of urinary incontinence. 3(suppl 1):S19–S26. Reflux Shapiro E. Update in pediatric urology [Meeting Review]. 3(1):10–17. Renal cell carcinoma Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Freedland SJ, Chao D, Pantuck AJ, et al. New diagnostic and therapeutic modalities for RCC, TCC, and testicular cancer [Literature Review]. 3(1):33–35. Freedland SJ, Chao D, Pantuck AJ, et al. Rethinking staging and treatment for renal cell cancer [Literature Review]. 3(3):162–163. Zisman A, Pantuck AJ, Freedland SJ, Belldegrun AS. Urology in the desert 2000 [Meeting Review]. 3(2):99–101. Saw palmetto Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Fagelman E, Lowe FC. Saw palmetto berry as a treatment for BPH. 3(3):134–138. Shock wave lithotripsy Conlin M. Current and coming in endourology [Meeting Review]. 3(1):6–9. Soft-tissue lesions Han M, Partin AW. Current clinical applications of the 111In-capromab pendetide scan (ProstaScint® Scan, Cyt-356). 3(4):165–171. Soy Moyad MA, Sakr WA, Hirano D, Miller GJ. Complementary medicine for prostate cancer: effects of soy and fat consumption. 3(suppl 2):S20–S30. Substance P Yoshimura N, Chancellor MB. Interstitial cystitis and bladder research: progress and future directions [Meeting Review]. 3(3):146–151. Suicide genes Djavan B, Yasutomo N. Prostate can- VOL. 3 NO. 4 2001 REVIEWS IN UROLOGY 223 Subject Index continued cer gene therapy—what have we learned and where are we going? 3(4):177–186. al. Determining the optimal treatment for advanced bladder cancer [Literature Review]. 3(3):159–162. Ureterocele Shapiro E. Update in pediatric urology [Meeting Review]. 3(1):10–17. Supraclavicular node Woo K, Wieczorek R, Torre P. Prostate adenocarcinoma presenting as a large clavicular mass. 3(2):102–105. Freedland SJ, Chao D, Pantuck AJ, et al. New diagnostic and therapeutic modalities for RCC, TCC, and testicular cancer [Literature Review]. 3(1):33–35. Ureteropelvic junction obstruction Conlin M. Current and coming in endourology [Meeting Review]. 3(1):6–9. Susceptibility genes Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. 3(suppl 2):S31–S38. Transrectal ultrasound Crawford ED, Miller GJ, Labrie F, et al. Prostate cancer pathology, screening, and epidemiology. 3(suppl 2):S2–S10. Targeted therapy Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. 3(suppl 3):S23–S28. Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. 3(suppl 2):S31–S38. Testicular cancer Freedland SJ, Chao D, Pantuck AJ, et al. New diagnostic and therapeutic modalities for RCC, TCC, and testicular cancer [Literature Review]. 3(1):33–35. Pound CR, Brawer MD, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. 3(2):72–84. Testicular growth arrest Paduch DA, Skoog SJ. Current management of adolescent variocele. 3(3):120–133. Tumor classification Freedland SJ, Chao D, Pantuck AJ, et al. Rethinking staging and treatment for renal cell cancer [Literature Review]. 3(3):162–163. Testosterone flare Thompson, Ian. Flare associate with LHRH-agonist therapy. 3(suppl 3):S10–S14. Tolteridone Appell RA. Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. 3(suppl 1):S15–S18. Torsion Shapiro E. Update in pediatric urology [Meeting Review]. 3(1):10–17. Transitional cell carcinoma Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Freedland SJ, Bui MHT, Chao D, et al. Biomarkers for early detection and optimized treatment for transitional cell carcinoma [Literature Review]. 3(4):210–212. Freedland SJ, Chao D, Pantuck AJ, et 224 VOL. 3 NO. 4 2001 Tumor markers Best of the 2001 AUA Annual Meeting [Meeting Review]. 3(4)193–206. Tumor marker tests Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. 3(2):85–93. Ultrasonography Grasso M, Caruso RP, Phillips CK. UPJ obstruction in the adult population: are crossing vessels significant? 3(1):42–50, 61. Grasso M, Caruso RP, Phillips CK. UPJ obstruction in the adult population: are crossing vessels significant? 3(1):42–50, 61. Ureteroscopy Conlin M. Current and coming in endourology [Meeting Review]. 3(1):6–9. Urge incontinence Appell RA. Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. 3(suppl 1):S15–S18. Nitti V. The prevalence of urinary incontinence. 3(suppl 1):S2–S6. Steers W. Potential targets in the treatment of urinary incontinence. 3(suppl 1):S19–S26. Urinary tract infection Decter RM. Update on vesicoureteral reflux: pathogenesis, nephropathy, and management. 3(4):172–178. Nickel JC. International symposium on UTI management [Meeting Review]. 3(1):18–19. Urinoma Shapiro E. Update in pediatric urology [Meeting Review]. 3(1):10–17. Urodynamics Dmochowski R. Evaluating the effectiveness of therapies for urinary incontinence. 3(suppl 1):S7–S14. Ultrasound contrast agents Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. 3(suppl 2):S31–S38. Urolithiasis Conlin M. Current and coming in endourology [Meeting Review]. 3(1):6–9. Ureter Eilber KS, Freedland SJ, Rajfer J. Obstructive uropathy secondary to ureteroinguinal herniation. 3(4):207–208. Vaccines, tumor Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. Tumor vaccines for metastatic renal cell carcinoma [Literature Review]. 3(1):21. REVIEWS IN UROLOGY Subject Index Varicocele Paduch DA, Skoog SJ. Current management of adolescent variocele. 3(3):120–133. Varicocelectomy Paduch DA, Skoog SJ. Current management of adolescent variocele. 3(3):120–133. Vesicoureteral reflux Decter RM. Update on vesicoureteral reflux: pathogenesis, nephropathy, and management. 3(4):172–178. Viral vectors Djavan B, Yasutomo N. Prostate cancer gene therapy—what have we learned and where are we going? 3(4):177–186. Vitamin D Goluboff ET, Hirano D, Thrasher JB, et al. New approaches to the treatment of advanced prostate cancer. 3(suppl 2):S69–S78. Vitamin D receptors Miller GJ, Brawer MK, Sakr WA, et al. Prostate cancer: serum and tissue markers. 3(suppl 2):S11–S19. Voiding dysfunction Dmochowski R. Evaluating the effectiveness of therapies for urinary incontinence. 3(suppl 1):S7–S14. Wounds Freedland SJ, Eilber KS, Palapattu GS, Rajfer J. Conservative management of a grade 4 renal laceration in a child. 3(1):40–41. VOL. 3 NO. 4 2001 REVIEWS IN UROLOGY 225